|
Study on the Health Economic Burden of Alzheimer's Disease in China
RECRUITINGSponsored by Xuanwu Hospital, Beijing
Actively Recruiting
SponsorXuanwu Hospital, Beijing
Started2023-07-01
Est. completion2026-06-30
Eligibility
Age40 Years – 100 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05995418
Summary
Alzheimer's disease (AD) presents a significant socio-economic challenge globally, with China experiencing a notable rise in its prevalence. This study addresses critical gaps in understanding AD's economic burden and quality of life (QoL) impacts on patients and caregivers in Mainland China.
Eligibility
Age: 40 Years – 100 YearsHealthy volunteers accepted
Diagnosed according to the National Institute on Aging-Alzheimer's 1.Association (NIA-AA) criteria for aMCI and AD. 2.Clinical Dementia Rating (CDR) score greater than or equal to 0.5 3.Have good visual, auditory, and language functions, or can complete neuropsychological assessments after correction. 4.Participants or their legal representatives sign informed consent. Exclusion criteria 1. History of stroke with neurological focal signs and imaging findings consistent with cerebral small vessel disease (Modified Fazekas score ≥2). 2. Presence of mental or neurological developmental delay. 3. Presence of other known conditions that may cause cognitive impairment. 4. Diagnosis of a disease that prevents completion of cognitive assessments. 5. Refusal to sign informed consent at baseline.
Conditions2
Alzheimer DiseaseAlzheimer's Disease
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorXuanwu Hospital, Beijing
Started2023-07-01
Est. completion2026-06-30
Eligibility
Age40 Years – 100 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05995418